VERADERMICS INC. O.N.

Veradermics introduced VDPHL01, a once-daily minoxidil tablet with extended drug release that the company says could reduce safety and usage limitations of current options and address a large, underserved market. Target group in the US: about 80 million affected people, including many women who lack an approved oral therapy. Three registration-relevant studies are ongoing; key data for men are expected in the second half of 2024, and for women in the first half of 2027. Management emphasized strong interest from physicians and patients but said clinical data are the critical next steps; no new financial figures were provided. » More on de.investing.com

Veradermics presented data on VDPHL01, an oral extended-release minoxidil tablet, at the Citigroup Biopharma Summit and sees it as a potentially safer option for hereditary hair loss in men and women. Studies in men showed visible effects after two months and an 86% improvement in hair density after six months; the women’s study 306 reached recruitment ahead of schedule. Three pivotal studies will provide key six-month and long-term data expected in the second half of 2026 and the first half of 2027. While Veradermics describes the safety profile as favorable compared with off-label oral minoxidil, no financial figures were disclosed. » More on de.investing.com

Veradermics stock dropped intraday by up to 4.8% to $97.90 under pressure from ongoing insider sales. CEO Reid Alexander Waldman and firms linked to directors reported large disposals in the days before (including 67,500, 100,000 and 750,000 shares). At the same time, the company reported a net loss of $23.5 million in Q2 2026 (prior year $15.6 million) and announced 16.77 million additional shares for potential sale, stoking dilution fears. Analysts such as Citi and Jefferies remain positive on the VDPHL01 pipeline but could not offset the short-term selling pressure. » More on de.investing.com